Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06411821 · ClinicalTrials.gov registry record · Phase 2
Ulixertinib in People With Histiocytic Neoplasms
A Phase 2 study of Histiocytic Neoplasms, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 8
- Study locations
NCT06411821: Recruiting Phase 2 study of Histiocytic Neoplasms, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06411821 is a Phase 2 study of Histiocytic Neoplasms that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06411821, a Phase 2 study of Histiocytic Neoplasms, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 8
- Study locations
Study Summary
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
Primary Outcome
Best overall response by PET is defined as the best response, according to PRC, recorded from the first day of study treatment until disease progression, recurrence, or death. Complete response Normalization of all lesions' (target and nontarget) SUV to background SUVliver (or SUVbrain for brain lesions) Partial response ≥50% decrease from baseline in sum of SUVs of all target lesions relative to SUVliver (or SUVbrain for brain lesions only) Progressive disease ≥50% increase from nadir in sum of
Conditions Studied
Interventions
- DRUG Ulixertinib
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk-Commack (Consent Only) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Consent Only) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Consent Only) - Montvale
Minnesota
- Mayo Clinic (Data Collection Only) - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT06411821 shows while recruiting
NCT06411821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Histiocytic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Ulixertinib is the first listed.
NCT06411821 lists 8 locations in 3 states (New York, New Jersey, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06411821 about?
NCT06411821 is a clinical study titled "Ulixertinib in People With Histiocytic Neoplasms". The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
What is the current status of trial NCT06411821?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2024-05-07. Estimated completion is 2027-05.
What conditions does trial NCT06411821 study?
This clinical trial studies the following conditions: Histiocytic Neoplasms.
What interventions are being tested in trial NCT06411821?
The interventions under investigation include: Ulixertinib (DRUG).
Who is sponsoring clinical trial NCT06411821?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06411821 being conducted?
This trial has 8 study locations across Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Histiocytic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06411821's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI